NCT04120233View on ClinicalTrials.gov

MW151-101: First-in-human Study of MW151

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

September 16, 2021

Study Completion Date

September 16, 2021

Conditions
Drug Toxicity
Interventions
DRUG

Placebo

Matched placebo administered orally

DRUG

MW151, 10mg

10 mg MW151, 1 x 10mg capsule administered orally

DRUG

MW151, 20mg

20 mg MW151, 1 x 20mg capsule administered orally

DRUG

MW151, 40mg

40 mg MW151, 2 x 20mg capsule administered orally

DRUG

MW151, 80mg

80 mg MW151, 1 x 80mg capsule administered orally

DRUG

MW151, 160mg

160 mg MW151, 2 x 80mg capsule administered orally

Trial Locations (1)

27705

Duke Clinical Research Institute, Durham

Sponsors
All Listed Sponsors
collaborator

Duke Clinical Research Institute

OTHER

collaborator

National Institute on Aging (NIA)

NIH

lead

Linda Van Eldik

OTHER